New York, United States - September 6, 2022 /MarketersMEDIA/ —
Biobetters provide a substantial difference in clinical efficacy and safety with fewer side effects or less frequent dosing, thus have been one of the hottest research directions for addressing unmet needs and reducing the cost burden on healthcare systems. Taking advantage of a series of technology platforms, Creative Biolabs now unveils a portfolio of Antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) enhanced biobetter products to improve global clients’ projects with ensured outcomes.
The professional scientists own profound knowledge of ADCC enhancement technologies and are proficient in utilizing Afuco™ Platform, Glymax™ Platform, Fucoanalog™ Platform, Fc Protein-Engineering Platform, Cross-Isotype Engineering Platform, CD16A Bispecific Antibody Engineering Platform, and Glyco- and Fc Protein Dual Engineering Platform to serve ADCC enhancement technology services and products.
Featured ADCC-enhanced biobetter products are listed below:
* Non-fucosylated Anti-Human CD20 Therapeutic Antibody
Creative Biolabs’ Afuco™ technology platform allows for the control of glycosylation level, thereby achieving ADCC-Enhanced Anti-CD20 Rituximab, a biobetter by reducing fucosylation of the Fc region of Rituximab, leading to an increased binding affinity for the FcyR receptor on immune effector cells.
* Highly Galactosylated Anti-HBV Surface Antigen Libivirumab
This biobetter antibody is of a high level of galactosylation, and is produced by the Fc engineering platform of Creative Biolabs.
The proprietary CDC-enhanced technology platforms at Creative Biolabs, covering Crea-Tag™ Platform, Fc Protein Engineering Platform, and Crosstype™ Engineering Platform, allow antibody conversion with limited or no chance to mutate to other potent cytotoxic antibodies, thus unleashing antibody potential to a greater level.
Featured CDC-enhanced biobetter products are listed below:
* Fc Engineered Anti-Human CD20 Therapeutic Antibody
Creative Biolabs’ advanced CDC-enhanced antibody platform gives Ofatumumab a greater binding capacity to C1q by mutating key amino acids of the Fc region, thereby achieving enhanced CDC activity.
* Fc Engineered Anti-Human HER2 Therapeutic Antibody
The isotype of this product is whole humanized antibody. By mutating key amino acids of the Fc region of Trastuzumab, this product exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
“We believe that our ADCC and CDC enhancement technology will be a safe and efficient expression tool, helping our clients accelerate the development and production of biobetter therapeutic antibodies on a flexible commercial scale. If what your research needs isn’t on a catalog, you can always ask for a custom solution.” said a senior scientist at Creative Biolabs.
Detailed information can be found on https://adcc.creative-biolabs.com/.
About Creative Biolabs
With more than a decade of exploration and expansion, Creative Biolabs has gathered a team of experts with solid knowledge regarding ADCC/CDC-enhanced therapeutic antibody discovery and development. Powered by Afuco™ technology, Creative Biolabs is confident to provide fully integrated solutions of expression optimization, recombinant protein production, antibody ADCC/CDC modification design, or cell line development.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://adcc.creative-biolabs.com/
Release ID: 89081223
If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.
